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Introduction
The first autoantibodies were discovered in the late 1940s, when 
both antinuclear antibodies (ANAs) and rheumatoid factors (RFs) 
were described as serum factors that could bind nuclear antigens 
and immunoglobulins, respectively (1, 2). ANA and RF were recog-
nized as diagnostic features of systemic lupus erythematosus (SLE) 
or RA, respectively, and as contributors to disease pathogenesis. It 
is now becoming increasingly clear that autoantibodies play a piv-
otal role in the pathogenesis of many diseases and that autoanti-
bodies mediate both systemic inflammation and tissue injury (3).
Here we focus mainly on the autoantibodies associated with the 
autoimmune diseases SLE and RA, and we discuss the recent devel-
opments on the generation of autoreactivity and the contribution 
of these antibodies to disease pathogenesis. We propose a model 
in which autoreactive B cells escape from tolerance because they 
bind TLR ligands and undergo clonal expansion because of contin-
uous exposure to antigen. Furthermore, the generation of immune 
complexes containing TLR ligands leads to systemic inflammation 
through the activation of innate immune cells. This systemic inflam-
mation is part of the disease process and further impairs tolerance 
mechanisms. While we cite data from studies of SLE and RA to sup-
port this paradigm, we believe the model has broader applications.
Central versus peripheral tolerance defects
During B cell development in the BM, autoreactivity is prevented 
through receptor editing, apoptosis, and induction of anergy in 
B cells expressing an autoreactive B cell receptor (BCR). When 
immature B cells express surface IgM, recognition of a self- 
antigen in the BM can induce these processes. Transitional B cells 
emerging from the BM continue to mature in the spleen, where 
additional tolerance mechanisms are in place. The exact mech-
anisms in this peripheral compartment are not fully understood, 
but they require ligand recognition by the BCR, similar to the tol-
erance checkpoints in the BM (4). After this stage, mature naive 
B cells can be activated upon antigen recognition, allowing them 
to enter the germinal center (GC). The GC is a site of rapid clonal 
expansion of B cells, affinity maturation, class switching, and dif-
ferentiation to memory B cells or plasma cells. A unique feature of 
GC-matured B cells is that they have undergone extensive somatic 
mutation of the antibody genes. As somatic hypermutation can 
give rise to de novo autoreactivity as well as enhance affinity of 
existing autoreactive B cells, additional tolerance checkpoints in 
the post-GC compartment have been suggested to effectively pre-
vent autoreactivity in memory B cells and plasma cells, through 
either apoptosis or receptor editing (5, 6).
The ability to sequence and clone Ig genes from individual B 
cells has opened the opportunity to study these tolerance check-
points in health and disease. The results from such studies using B 
cells from healthy individuals suggest that a high number of auto-
reactive B cells is generated in the BM and that sequential toler-
ance checkpoints lead to a gradual decrease in autoreactivity as 
the B cells mature (7).
The presence of autoreactive B cells in healthy individuals 
indicates that central tolerance is not sufficient to remove all auto-
reactive B cells with self-targeting BCRs. Indeed, it is well-estab-
lished that both the B1 subset and marginal zone B subset contain 
high numbers of autoreactive B cells, and in animal models B 
cells from these subsets can give rise to pathogenic autoreactivity 
(8–10). Although defects in early B cell tolerance have been found 
in patients with autoimmune disease (11, 12), current data suggest 
that most of their autoreactive B cells are derived from nonautore-
active precursors. Autoantibodies derived from memory B cells in 
systemic autoimmune disease are often class-switched and highly 
somatically mutated, which suggests that they have been involved 
in GC reactions (13–19). Memory B cells making anti-DNA antibod-
ies and anticitrullinated protein antibodies (ACPAs) in patients with 
autoimmune disease are thought to be derived from nonautoreac-
tive precursors because back-mutation of their somatic mutations 
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engage in direct antigen-specific interactions with ACPA-produc-
ing B cells when citrullinated antigens are internalized through 
BCR-dependent recognition. However, the T cell specificities 
involved in the activation of other autoreactive B cells, such as 
DNA-reactive B cells, are not known. Some studies suggest that 
the epitopes for B cells and T cells do not necessarily need to be 
the same. For example, B cells can internalize multimolecular 
complexes through BCR-mediated recognition and can then pro-
cess peptides from different proteins present in the complex. This 
internalization of multimolecular complexes clearly enables pro-
cessing of nucleoproteins capable of binding DNA in lupus-prone 
mice and SLE patients (23–26).
T cell help for autoantibody-producing B cells can also orig-
inate from T cell responses to foreign antigens through molecu-
lar mimicry between viral or bacterial antigens and self-antigens 
(27–30). Activation of nonautoreactive T cells by foreign antigens 
can lead to activation of B cells that recognize the foreign antigen 
but also cross-react with a self-antigen (31). It is hypothesized that 
such activation can lead to selection and maturation of high-affin-
ity self-reactive B cells.
In addition to the typical GC response, class switching and 
somatic hypermutation can also occur outside of the classical GCs. 
In several autoimmune diseases, ectopic lymphoid structures can 
develop, usually in the target organ, such as the synovial tissue in 
RA or the kidney in SLE. These structures closely resemble the GC 
with the presence of B/T lymphoid clusters that include T follicular 
helper cells and follicular dendritic cells. Ectopic lymphoid organs 
are often associated with the production of high levels of autoanti-
bodies, suggesting that local activation of these cells can contribute 
to T cell–dependent B cell differentiation, as in the GC (32, 33).
Target antigens for autoantibodies
Autoantibodies can be directed against a variety of molecules, such 
as nucleic acids, lipids, and proteins, and these target antigens can 
be located in the nucleus or cytoplasm, on the cell surface, or in the 
to germline sequences removes their autoreactivity (17, 18). Fur-
thermore, although naive polyreactive B cells can recognize citrul-
linated proteins or DNA and therefore could give rise to ACPAs and 
anti-DNA–producing plasma cells, the affinity of ACPAs and anti-
DNA antibodies from naive B cells is greatly reduced compared 
with antibodies in patient serum, suggesting that these naive B cells 
have undergone affinity maturation before developing into plasma 
cells (11, 18). While sequence analyses of autoantibodies have thus 
far only been performed for a limited number of patients and access 
to plasma cells is limited by the unavailability of BM samples, there 
is consistent evidence that many autoreactive B cells in autoim-
mune disease mature in the GC.
Taken together, these data suggest that defects in central and 
early peripheral tolerance checkpoints are present in autoimmune 
disease patients, but the defects in early tolerance checkpoints do 
not necessarily lead to the generation of pathogenic autoantibod-
ies. As studies point to an important role of somatic hypermuta-
tion during GC reactions as a source of autoreactivity, post-GC 
checkpoints are likely defective in patients with autoimmune dis-
ease, but our understanding of these checkpoints is limited.
T cell help for autoantibody production
Development of high-affinity antibodies requires cognate B 
cell/T cell interactions to initiate and sustain the GC. Somatically 
mutated autoantibodies in autoimmune disease are thought to be 
derived through T cell–dependent pathways, especially because 
the presence of autoantibodies is often correlated with the pres-
ence of specific HLA alleles (20, 21). However, at present little is 
known about the specificity of T helper cells that are able to stimu-
late autoantibody-producing B cells.
The most direct pathway for T cell helper function is for T 
cells to recognize the same antigen as the B cells. In RA, one of 
the genetic risk HLA alleles, HLA-DRB1*0401, has recently been 
associated with presentation of citrullinated peptides, allowing 
for activation of citrulline-specific T cells (22). These T cells may 
Table 1. Autoantibody recognition in systemic autoimmune disease
Antigen location Antibody Antigen Disease PRR recognition
Nuclear Anti-Ro (SS-a) Ro-RNP complex SLE, Sjögren’s syndrome TLR7
Anti-La (SS-B) La antigen SLE, Sjögren’s syndrome TLR7
Anti-Sm Small nuclear RNP SLE TLR7
Anti-dsDNA dsDNA SLE TLR9
Anti-histone Histones SLE (drug-induced) TLR2 and TLR4
Anti–Scl-70 Topoisomerase I Systemic sclerosis
Anti-centromere Centromere Systemic sclerosis/CREST syndrome
Cytoplasmic/ mitochondrial ANCA Myeloperoxidase (p-ANCA) and  
proteinase 3 (c-ANCA)
Vasculitis, Wegener’s granulomatosis
ACA Cardiolipin Antiphospholipid syndrome, SLE NLRP3
Modified proteins ACPA Citrullinated proteins RA TLR4
Anti-Carp Carbamylated proteins RA
Extracellular RF RF (IgG) RA
Lupus anticoagulant Phospholipids Antiphospholipid syndrome TLR4?
α3 Chain of basement membrane  
collagen (type IV collagen)
α3 Chain of basement membrane  
collagen (type IV collagen)
Goodpasture’s syndrome
ACA, anti-cardiolipin antibody.
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is substituted for arginine (34, 35). Most of these antigenic citru-
llinated antigens are extracellular proteins, although intracellular 
citrullinated proteins have also been identified as targets of ACPAs. 
To date, it is unknown whether intracellular or extracellular citrulli-
nated antigens are the main driver of the ACPA response.
B cell propagation in response to self-antigen or 
foreign antigen
The intracellular location of many autoantibody targets raises the 
question of how these antigens can drive clonal expansion, a pro-
cess that requires the recognition of antigens through the BCR, 
which occurs in the extracellular space.
Two main hypotheses exist that can explain how autoantibodies 
arise that recognize intracellular self-antigens (Figure 1A). The first 
theory proposes that apoptosis plays an important role as a source of 
nuclear and cytoplasmic self-antigens. During this process of pro-
grammed cell death, apoptotic blebs appear on the cell surface and 
microparticles can be released from the cell, both of which contain 
several cytoplasmic and nuclear components. These include several 
extracellular milieu. When analyzing autoantibodies in the most 
common systemic autoimmune diseases, it is striking that most of 
them target ubiquitously expressed intracellular molecules (Table 
1). Among these, ANAs, a group of heterogeneous antibodies tar-
geting multiple distinct nuclear components, are the most com-
mon. The molecules recognized by ANAs are normally present 
in the nucleus and therefore are not accessible to antibodies or B 
cells. It is only in conditions of cell death that nuclear contents are 
released into the extracellular environment.
RA can be considered an exception, as the autoantibodies in 
RA do not generally target intracellular molecules. The classical 
example is RF, which recognizes the Fc portion of IgG, an abundant 
protein in serum. Another important group of autoantibodies in 
RA targets modified proteins, with ACPAs being the best charac-
terized. ACPAs show a very high specificity in clinical diagnostics 
for RA and are present in the majority of patients with RA. These 
antibodies recognize a variety of proteins such as fibrinogen or 
fibrin, vimentin, type II collagen, α-enolase, and histones that have 
undergone a posttranslational modification in which citrulline 
Figure 1. Mechanisms for autoantibody production: apoptosis, antigen modification, and cross-reactivity. Three models can explain the recognition of 
intracellular antigens by autoantibodies. (A) Cell death through apoptosis or necrosis leads to extracellular exposure of intracellular self-antigens through 
release of intracellular contents into the extracellular environment, formation of apoptosis blebs, or NETosis. If clearance mechanisms are insufficient, 
there may be recognition of these antigens by B cells and autoantibody production. (B) Modification of self-antigen generates neoantigens, to which B 
cells have not been tolerized. (C) Autoantibody production arises from responses to foreign antigens, which cross-react with self-antigens.
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mally shown, but it is likely that the citrulline epitopes on differ-
ent antigens form the basis for cross-reactivity between intra- 
and extracellular antigens. In cardiomyopathy, autoantibodies 
targeting cardiac myosin, an intracellular antigen, have been 
shown to cross-react with the β-adrenergic receptor, thereby 
inducing stimulation of cardiomyocytes. These findings suggest 
that cross-reactivity between intra- and extracellular antigens 
can drive clonal expansion.
Similarly, cross-reactivity between foreign antigens and 
self-antigens can drive the expansion of autoreactive B cells 
(Figure 1C). Several autoantibodies exhibit such cross-reac-
tivity: dsDNA autoantibodies cross-react with pneumococcal 
bacteria and Epstein-Barr virus (29, 45) and anti-neutrophil 
cytoplasm antibodies (ANCAs) recognize the bacterial adhesin 
FimH (28). However, this cross-reactivity between foreign anti-
gens and intracellular self-antigens still requires the release of 
intracellular antigens through apoptosis or cross-reactivity to 
surface antigens in order for autoantibodies to bind and exert 
their pathogenic activity.
We speculate that B cells with BCRs that recognize only intra-
cellular antigens will propagate less well than those that cross- 
react with more ubiquitous cell surface or extracellular antigens. 
Therefore, the basis for clonal expansion of many autoreactive B 
cells can be found in their cross-reactivity.
TLR recognition and its role in escape from 
tolerance
Many antigens recognized by autoantibodies are able to trigger 
pattern recognition receptor (PRRs), including TLRs and Nod-
Like receptors (NLRs). These receptors are listed in Table 1 and 
include DNA, RNA, citrullinated fibrinogen, cardiac myosin, 
cardiolipin, and oxidated phospholipids (51–56).
B cells express several TLRs for nucleic acids, including 
TLR7 and TLR9. Engagement of these TLRs activates B cells. 
Notably, many antigens recognized by autoantibodies are lig-
ands for B cell TLRs (Table 1), suggesting a role for TLR rec-
ognition in the breakdown of tolerance against these antigens. 
Indeed, mice deficient in TLR7, TLR9, or the TLR-associated 
signaling adaptor MyD88 are partially protected against devel-
opment of ANAs and lupus-like symptoms (57–60). This protec-
tion derives from the effects that TLR ligation has on reducing 
B cell tolerance.
Combined BCR and TLR ligation by nuclear antigens has 
been shown to induce a synergistic signaling response, mediated 
by colocalization of TLR9 and antigen internalized through BCR 
(61–63). Thus, self-antigens able to activate endosomal TLRs 
and BCRs will induce robust activation in B cells. Some studies 
suggest that TLR activation of immature B cells can dysregulate 
central tolerance pathways (64–66). We hypothesize that TLR 
ligation might also explain the failure of peripheral tolerance in 
autoimmune disease. Several studies show increased TLR expres-
sion and function in activated or memory B cells compared with 
immature B cells, allowing for robust activation through TLR in 
the GC (67–70). As tolerance in the GC is thought to be driven by 
a survival advantage through affinity-driven selection, combined 
BCR/TLR ligation in the GC may facilitate positive selection and 
escape from tolerance.
of the intracellular antigens recognized by autoantibodies, such as 
histones, dsDNA, RNA, ribonucleoproteins (RNPs), and myeloper-
oxidase and proteinase 3 in neutrophils (36–39). Furthermore, the 
process of apoptosis induces several modifications in the nucleus, 
including histone citrullination and acetylation, which can be recog-
nized by autoantibodies in RA and SLE, respectively (40, 41). Apop-
totic blebs are normally quickly engulfed by phagocytes to prevent 
immune activation (42); however, a failure to do this, due either to a 
genetic defect in one of the apoptosis clearance pathways (as often 
seen in autoimmune disease) or to excessive release of these blebs 
due to inflammation, allows for the sustained presence of these 
self-antigens in the extracellular environment (43).
Another pathway for propagation of autoantibody responses 
toward intracellular antigens is through cross-reactivity with 
extracellular antigens. An example of such cross-reactivity is anti-
dsDNA antibodies in SLE, which have been shown to recognize 
antigens in the glomerular basement membrane, where these 
autoantibodies can deposit (44–47). While the binding of some 
anti-dsDNA antibodies to glomeruli depends on the presence of 
nucleosomes containing DNA on the glomerular membrane, the 
contribution of cross-reactivity to renal pathology has also been 
demonstrated (48, 49).
In RA, ACPAs can target both intracellular and extracel-
lular citrullinated antigens that arise during an inflammatory 
response (Figure 1B and refs. 34, 35, 50). It has not been for-
Figure 2. Proposed role of PRR activation and cross-reactivity in 
expansion of autoreactive B cells and their effector functions. (A) 
Self-antigens that bind PRRs can activate B cells. We hypothesize that 
the combined recognition of self-antigens by BCRs and PRRs is required 
for tolerance escape in autoreactive B cells. (B) B cells require recognition 
of antigen through their BCR for clonal expansion. As most autoantibod-
ies recognize intracellular self-antigens, cross-reactivity to cell surface 
or extracellular molecules enhances clonal expansion and differentiation 
into memory and plasma cells.
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Pathogenicity of autoantibodies
The pathogenicity of autoantibodies has been extensively debated. 
Proof of pathogenicity is derived from the ability of autoantibod-
ies to induce cellular damage or immune activation in vitro or to 
passively transfer autoimmune disease in animal models, as well 
as the effectiveness of B cell–targeting therapies. Although such 
evidence is not established in all autoimmune diseases, the most 
common systemic autoantibodies, such as ANAs and ACPAs, are 
considered pathogenic.
Pathogenicity has been most thoroughly studied in mouse 
models with lupus-like disease. Several studies have shown that 
passive transfer of anti-DNA antibodies or expression of autore-
active transgenic BCRs can cause inflammation in the kidneys, 
although not all antibodies have equal capacity to do so (78–80). 
In contrast, only limited evidence of the pathogenicity of ACPAs 
or RF is present in mouse models of arthritis. This may be due to 
the absence of these autoantibodies in most mouse models; how-
ever, when ACPAs are adoptively transferred into mice with low-
level inflammation caused by anti-collagen antibodies, ACPAs 
enhances arthritis, directly implicating them in the inflammatory 
process in the joint (80, 81).
Autoantibody effector functions
The effector functions that are employed by autoantibodies resem-
ble those of antibodies in general and are therefore largely depen-
dent on their isotype. Specific autoantibody isotypes are present in 
different diseases, with IgA antibodies present in antiphospholipid 
syndrome and IgE autoantibodies present in SLE (82–84). IgM 
and IgG autoantibodies are the most abundant. IgM autoantibod-
ies are also present in healthy individuals and are therefore often 
considered to be less pathogenic (85). IgM is a potent activator of 
the complement component 1, q subcomponent (C1q), which has 
recently been shown to inhibit TLR activation by acting as a lig-
and for the inhibitory leukocyte-associated immunoglobulin-like 
receptor 1 (LAIR1), suggesting that IgM might inhibit immune 
effector responses (86). In support of this model are experiments 
that showed that an inability to secrete IgM in B cells leads to IgG 
autoantibody production in mice (87).
A major pathway for immune activation and tissue damage 
for systemic autoantibodies is through formation of immune com-
plexes. In situ immune complexes form when antigen is present 
at specific sites within tissues. Different monoclonal anti-DNA 
antibodies have distinct patterns of renal deposition, depending 
on their specificity and cross-reactivity (45). Although RA is asso-
ciated with the presence of circulating immune complexes, the 
disease is mainly limited to the joints. This is thought to arise in 
part from preferential binding of antibodies to citrullinated pro-
teins present in the synovium (88).
Immune complexes formed in situ can activate the comple-
ment system and Fc receptors, leading to tissue inflammation 
and damage. Complement activation by autoantibodies has 
been shown to occur through both classical and alternative path-
ways (89, 90) and can lead to direct cell lysis and damage as well 
as recruitment of leukocytes to further enhance inflammatory 
responses. Complement-mediated cell lysis has also been shown 
to serve as a source of antigen, such as DNA, RNP, and citrulli-
nated proteins (91).
TLR engagement and T cell–independent B cell 
activation
Increased levels of the cytokine B cell–activating factor of the tumor 
necrosis factor family (BAFF) and TLR activation have been impli-
cated in T cell–independent activation of autoreactive B cells (60, 
71). In vitro, increased TLR activation and BAFF levels have been 
shown to trigger activation-induced cytidine deaminase expres-
sion, which also induces somatic hypermutation and class switch-
ing in naive B cells (72). Another study showed that neutrophil- 
derived cytokines including BAFF can induce somatic hypermuta-
tion and class switching in marginal zone B cells (73). Furthermore, 
several studies showed that TLR activation can directly instigate 
IgG class switching and T cell–independent plasma cell differen-
tiation, thereby possibly circumventing the requirement for T cell 
help in the peripheral compartment (57, 74, 75).
It is not clear whether these T cell–independent B cell acti-
vation pathways are sufficient to induce the levels of somatic 
hypermutation that are observed in autoreactive IgG+ memory 
B cells. Importantly, TLR activation and T cell help might inter-
act to induce somatic mutation. TLR activation of B cells can 
enhance antigen presentation and increase surface expression of 
co-stimulatory molecules, which will facilitate non–antigen-spe-
cific interaction with T cells (76, 77). Therefore, TLR activation 
can enhance somatic mutations in T cell–dependent or –inde-
pendent B cell responses.
Together, these data support an important role for TLR acti-
vation in the development of autoantibody responses, especially 
when activated in combination with BCRs. B cells with BCR 
specificity for a TLR ligand may be enabled to escape tolerance 
mechanisms. If such a BCR binds a ubiquitous antigen, such 
as a cell membrane or extracellular antigen, clonal expansion 
occurs, with affinity maturation and differentiation to a plasma 
cell (Figure 2, A and B).
Figure 3. The role of PRR activation by self-antigens in autoantibody 
pathogenesis. During autoimmune responses, inflammation can lead to 
cell death and release of endogenous PRR or TLR ligands. When recog-
nized by autoantibodies, these ligands can activate myeloid immune cells 
through both Fc receptors and PRRs, leading to an enhanced inflammatory 
response. This response, in turn, can lead to tissue destruction and release 
of ligands for PRRs and autoantibodies, which further amplifies the 
chronic inflammatory response.
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Activating Fc receptors are expressed by a variety of cells, 
particularly by immune cells of the myeloid lineage. Autoanti-
bodies have been shown to activate these immune cells through 
FcγR-dependent pathways (92–94). In vivo, FcγR-deficient mice 
often show decreased autoimmunity (95, 96). The capacity of IgG 
to activate Fc receptors contributes to their increased pathoge-
nicity compared with IgM autoantibodies. However, IgM-RF was 
recently shown to enhance FcγR-dependent activation by ACPAs, 
demonstrating that isotypes other than IgG can contribute to 
pathogenesis (97).
Clinical evidence for autoantibody pathogenesis
Most autoantibodies are present years before disease onset and 
thus are not merely a consequence of inflammation (98–100). 
Furthermore, for ACPAs, there is evidence for epitope spreading, 
affinity maturation, isotype switching, and glycosylation changes 
before clinical symptoms start. Each of these changes is associ-
ated with greater pathogenic potential (101–105). In addition to 
the changes in the intrinsic properties of autoantibodies before 
disease onset, the target organ can also become susceptible to 
autoantibody deposition or binding. This is in accordance with the 
multiple-hit theory of autoimmunity, in which genetic and envi-
ronmental factors induce an initial break in tolerance leading to 
production of autoantibodies. A “second hit” is needed for the 
antibody to exert pathogenic effects and to sustain the inflam-
matory cascade of the autoimmune response. This phenomenon 
is perhaps most clearly illustrated in myositis, in which the auto-
antibodies bind regenerating myocytes and thus sustain a cycle of 
injury and regeneration (106).
Chronic inflammation
As stated above, many autoantibodies target ubiquitously 
expressed intracellular molecules. For antibodies to bind these 
targets, these antigens need to be released to the extracellular 
environment, where antibodies or immune complexes are depos-
ited. As the self-antigens are ubiquitously present, autoantibody 
effector mechanisms fail to eliminate the antigen, causing inflam-
matory injury to tissues that leads to additional release of these 
intracellular antigens. This process causes a vicious cycle wherein 
each disease flare can initiate further autoantibody production 
and tissue injury (107–109). Furthermore, combined TLR- and Fc 
receptor–mediated activation of myeloid cells often leads to an 
enhanced inflammatory response that is thought to contribute to 
the chronicity of inflammation (51, 94, 110, 111). Therefore, those 
self-antigens that can most potently activate B cells because they 
are TLR ligands may also potently enhance pathogenic inflamma-
tory responses (Figure 3).
Conclusions
A break in tolerance against self-antigens or modified self-anti-
gens can lead to the production of autoantibodies. Such a breach 
in tolerance can originate from a lack of clearance of apoptotic 
debris, inflammation-mediated modification of self-antigen, or 
cross-reactivity between foreign and self-antigens. Some auto-
antibodies cross-react between an intracellular antigen that is a 
TLR ligand and cell surface or extracellular antigen, allowing for 
continued B cell activation and autoantibody-mediated injury. 
After initiation of autoantibody production, inflammation may 
cause release of intracellular or modified self-antigens, leading 
to antibody effector function and instigation of clinical symp-
toms as well as to the propagation of the autoreactive B cell 
clones. These pathogenic processes are mainly mediated by IgG 
autoantibodies, although other isotypes may contribute. TLRs 
play an important role during both initiation and pathogenesis 
of autoantibody responses, as they can recognize several self- 
antigens such as alarmins. TLR activation can enhance the initia-
tion of autoantibody responses and can synergize with Fc-medi-
ated effector functions. We speculate that those autoreactive B 
cells that can escape tolerance and expand and differentiate in 
response to antigen have BCRs that bind antigens that associate 
with or are TLR ligands. Reactivity with abundant cell surface or 
extracellular antigens permits the clonal expansion and survival 
of these B cells once inflammation has subsided. Furthermore, 
this cross-reactivity may contribute to their pathogenicity.
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